Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor.
about
From oligonucleotide shapes to genomic SELEX: novel biological regulatory loopsModified Nucleoside Triphosphates for In-vitro Selection TechniquesFrom selection hits to clinical leads: progress in aptamer discoveryGeneration of Aptamers with an Expanded Chemical RepertoireIn vitro selection using modified or unnatural nucleotidesTowards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancerInfluence of target concentration and background binding on in vitro selection of affinity reagentsInhibition of cell proliferation by an anti-EGFR aptamerDifferential SELEX in human glioma cell linesFit for the Eye: Aptamers in Ocular DisordersIn vitro selection using a dual RNA library that allows primerless selectionVascular endothelial growth factor as an anti-angiogenic target for cancer therapyFunctional nucleic acid sensorsShort bioactive Spiegelmers to migraine-associated calcitonin gene-related peptide rapidly identified by a novel approach: tailored-SELEXSpiegelmers: biostable aptamers.RNase-stable RNA: conformational parameters of the nucleic acid backbone for binding to RNase T1.A Y2 receptor mimetic aptamer directed against neuropeptide Y.Mirror-image RNA that binds D-adenosine.A nuclease-resistant RNA aptamer specifically inhibits angiopoietin-1-mediated Tie2 activation and functionDevelopment of the anti-VEGF aptamer to a therapeutic agent for clinical ophthalmology.Aptamers: from bench side research towards patented molecules with therapeutic applications.Recent developments in protein and cell-targeted aptamer selection and applicationsAptamers from cell-based selection for bioanalytical applicationsNucleic acid aptamers: clinical applications and promising new horizonsPotential therapeutic application of antisense oligonucleotides in the treatment of ocular diseases.A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165Structural requirements for the procoagulant activity of nucleic acids.An isothermal system that couples ligand-dependent catalysis to ligand-independent exponential amplificationRAPID-SELEX for RNA aptamersNucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic AgentsAptamers: current challenges and future prospects.Degradation of nuclease-stabilized RNA oligonucleotides in Mycoplasma-contaminated cell culture media.High affinity ligands from in vitro selection: complex targets.In vitro evolution of chemically-modified nucleic acid aptamers: Pros and cons, and comprehensive selection strategiesArchitecture of high-affinity unnatural-base DNA aptamers toward pharmaceutical applications.Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases.In vitro selection using modified or unnatural nucleotides.Autocatalytic aptazymes enable ligand-dependent exponential amplification of RNA.In situ Protein Detection for Companion Diagnostics.A novel C5a-neutralizing mirror-image (l-)aptamer prevents organ failure and improves survival in experimental sepsis
P2860
Q24671006-B2AE5034-AE5B-438B-9D9C-B1A9A10A0DB1Q26747256-9B49DD3D-4E9B-49B3-A140-CCC726E38E1FQ26752799-96B92E8E-C1B1-4313-BCD4-9A916AF280D2Q26782794-F0A5DA67-3E57-4695-A8A6-E3E693027808Q26864079-9E4CDF32-1EB6-4455-A931-411C5FE21DC3Q28291499-203C1D4B-337E-4FE7-8E3A-91C0586EF030Q28482831-71C2A647-C3B7-48D8-AB15-4EC601540F44Q28743866-34EDC2B1-831A-4DBD-9B73-8DCEDF9FD987Q28750173-6C3FA9D0-BA1C-4C0D-B3F5-B075E19DA828Q28828283-5700E4AF-9FAC-4863-9DF7-EE80A6BB2BA2Q29036552-3CAEF27E-A1A7-4E1E-A635-710C64312CC3Q30455612-9B8B8F1D-2121-48B4-85B9-0107B4F4F229Q30481633-DFCC6054-C1AF-4383-A130-EB5502322144Q30823550-DF22CF10-D433-4272-BC02-3F63769FF7F8Q31005222-B62294C9-7BC6-4EB8-8194-4F656F7B434DQ31006328-23270C8E-839C-4444-ADD2-94EA3388D27AQ31033093-E197B48D-DC38-4085-B00E-CE40C81F4212Q32060741-101C7DB1-FFB2-4C92-ACE9-028FD81A6AD7Q33387645-32FE8ED7-4295-4AD2-B4C4-E9DD193862B9Q33492343-64D99A03-F09D-4890-B9D2-2CDA3195A5A0Q33512089-EF13F60F-0325-4A75-B05B-9307B9B67D96Q33908491-DE3B1975-FD94-4C43-8727-E80F679FE359Q33920514-048CA3B7-2784-4C96-9C8A-DFFD2555362DQ34028112-0A3F7514-E90C-4F97-8F33-D80107C57706Q34240839-B5859BC4-D1C4-4B6A-867D-3160E083C9D4Q34245063-56DFD657-0751-4BB7-AFA0-68ECD19FB587Q34505358-175BBCC9-B24C-4350-A8AC-62C9CD7E8AB5Q34625150-4F80AAC8-2587-4C4E-86F1-8AC28A858052Q35077674-98975EAA-66C6-489B-9098-ACD697B5C6D1Q35309726-4F2E7109-BD00-4C94-92F6-AD592336575AQ35859041-350B2B70-13B0-4C09-BEF4-1099F08B4D2CQ35867148-FEA6527F-C5E8-4129-86AA-1BFFCADBA8D7Q35974349-369F80F7-2FBD-4FDB-9EF5-18C48CBF265FQ36156320-BA2022F3-41B6-4E85-BBB2-BBCA0F2F9E50Q36392650-4BC7E88A-BBAF-44E0-9673-359178945CBCQ36673663-E71F5EB8-5529-451D-8C4D-AB9132223F2BQ37144658-565EE834-7179-44DF-804B-C1D418F62973Q37226028-0705581B-47CE-49A5-BA93-DC2C8E343452Q37270405-45665D5D-922D-43F8-8067-2AB422076C18Q37393792-B0033256-4260-486F-8E1A-4A981297AE96
P2860
Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Nuclease-resistant nucleic aci ...... lar endothelial growth factor.
@en
type
label
Nuclease-resistant nucleic aci ...... lar endothelial growth factor.
@en
prefLabel
Nuclease-resistant nucleic aci ...... lar endothelial growth factor.
@en
P2093
P1476
Nuclease-resistant nucleic aci ...... lar endothelial growth factor.
@en
P2093
B D Feistner
D Jellinek
F M Jucker
P304
P356
10.1016/1074-5521(95)90032-2
P577
1995-10-01T00:00:00Z